Shares of Progyny Inc (NASDAQ:PGNY) saw unusually-strong trading volume on Monday . Approximately 1,230,822 shares were traded during mid-day trading, an increase of 88% from the previous session’s volume of 653,173 shares.The stock last traded at $28.54 and had previously closed at $26.64.

A number of equities analysts have issued reports on PGNY shares. Piper Jaffray Companies started coverage on Progyny in a report on Wednesday, November 27th. They issued an “overweight” rating and a $33.00 price objective for the company. Leerink Swann started coverage on Progyny in a report on Wednesday, November 27th. They issued an “outperform” rating and a $28.00 price objective for the company. JPMorgan Chase & Co. started coverage on Progyny in a report on Wednesday, November 27th. They issued an “overweight” rating and a $26.00 price objective for the company. Goldman Sachs Group started coverage on Progyny in a report on Tuesday, November 19th. They issued a “buy” rating and a $33.00 price objective for the company. Finally, Citigroup started coverage on Progyny in a report on Wednesday, November 27th. They issued a “buy” rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Progyny presently has an average rating of “Buy” and a consensus price target of $29.67.

In other news, insider Peter Anevski sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $45.20, for a total transaction of $904,000.00. Also, EVP Karin Ajmani sold 384,003 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $16.39, for a total value of $6,293,809.17. Insiders have sold 1,933,004 shares of company stock valued at $32,258,136 over the last 90 days.

Progyny Company Profile (NASDAQ:PGNY)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Story: What are high-yield dividend stocks?

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.